Sanofi's CEO, Chris Veihbacher, said that the parent corporation may look to provide fill/finsh capability to Genzyme following the completed acquisition. He stressed, however, that any such move woudl be further in the future as Sanofi will concentrate on executing Genzyme's existing manufacturing recovery plan following the deal close.
So for the near term, Hospira can rest soundly on the knowledge that it will continue to provide fill/finish services for Cerezyme and Fabrazyme until supplies can be built and stabilized. Over the past two years, both these drugs have been plagued by supply issues due to problems at Genzyme's Allston manufacturing site - which is still operating under FDA oversight as part of the consent decree.
Posted by Bruce Lehr Feb 17th 2011.